A post-hoc analysis of the Prasinezumab trial in early Parkinson's disease
Dr. Gennaro Pagano discusses a post-hoc analysis of the PASADENA trial, which investigated the monoclonal antibody Prasinezumab for early Parkinson's disease. The analysis observed differences in motor progression trajectories between patients who received the active treatment…